Yonika Larasati obtained a Bachelor of Pharmacy degree from Universitas Gadjah Mada, Indonesia, and a Master of Biological Sciences degree from Nara Institute of Science and Technology, Japan. Her work has explored natural products for their potential in cancer chemoprevention. Currently, Yonika is pursuing a PhD in biomedical science in the laboratory of Prof. Vladimir Katanaev at the University of Geneva, Switzerland. Her research is part of a translational drug discovery and development project targeting the Wnt pathway in cancer. It involves high-throughput screening of small molecules and validating their pre-clinical anticancer properties.

Cédric Boudou obtained his PhD in organic chemistry from the University of Caen, France, in 2004. Cédric started his career as a medicinal chemist at Janssen-Cilag and Idealp Pharma. He then worked for five years at Addex Therapeutics and for four years at AC Immune. During this period, he was involved as a medicinal chemist and project leader in several small molecule drug discovery programs for neurodegenerative diseases. Cédric currently holds a Junior Lecturer position in the group of Prof. Vladimir Katanaev at the University of Geneva, where he leads medicinal chemistry activities in the development of anticancer drugs.

Alexey Koval graduated from the biochemistry and biotechnology program of M.V. Lomonosov's Moscow Academy of Fine Chemical Technology. He started his PhD thesis in 2008 in Konstanz, Germany and completed it in 2012 at the University of Lausanne, Switzerland, working on analysis of the G-protein coupled receptor (GPCR) properties of mammalian Frizzled receptors. As a postdoctoral researcher at the University of Lausanne, Alexey expanded this project into a search for compounds that target Wnt signaling. Alexey’s current work, as a senior scientist in the laboratory of Prof. Katanaev at the University of Geneva, guides the biology aspects of translational research on anti-Wnt anti-cancer agents.

Vladimir Katanaev studied biochemistry at Krasnoyarsk State University, Russia. He obtained his PhD in 2000 at the University of Fribourg, Switzerland, working on leukocyte chemotaxis. As a postdoc at Columbia University, New York, he then studied Wnt signaling in Drosophila. From 2005 to 2011, he led a research group at the University of Konstanz, Germany, that investigated Wnt signaling in animal development and carcinogenesis. In 2011, he joined the University of Lausanne as an associate professor. Vladimir combined his interests in fundamental and translational research when he joined the Faculty of Medicine at the University of Geneva, as full professor and chair in translational oncology, in 2018.

© 2021 The Author(s). Published by Elsevier Ltd.